Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-0873 2% Cream
MK-0873 2% · 1 trial · 2 indications
Each lesion was evaluated for 3 components: erythema, induration, and scaling. Each component was given a score using the following scale: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked, with increasing score reflecting increased lesion severity. The TLS score (range 0 to 12) is calculated as the sum of the 3 components.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D. |
| Treatment Sequence 2 | EXPERIMENTAL | Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D. |
| Treatment Sequence 3 | EXPERIMENTAL | Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D. |
| Treatment Sequence 4 | EXPERIMENTAL | Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D. |
| Treatment Sequence 5 | EXPERIMENTAL | Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D. |
| Treatment Sequence 6 | EXPERIMENTAL | Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D. |
| Treatment Sequence 7 | EXPERIMENTAL | Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D. |
| Treatment Sequence 8 | EXPERIMENTAL | Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D. |
| Name | Type | Description |
|---|---|---|
| MK-0873 2% Cream | DRUG | Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area. |
| MK-0873 vehicle (placebo) Cream | DRUG | Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area. |
| Calcitriol Cream | DRUG | Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area |
Inclusion Criteria * Is a male or female 18 to 65 years of age * Female subjects of reproductive potential must have a negative serum pregnancy test at screening and agree to use and/or have their partner use two (2) acceptable methods of birth control * Has a Body Mass Index (BMI) ≤36 kg/m\^2 (up ...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
MK-0873 2% is an investigational small molecule developed by Merck & Company, Inc. (MRK) for the treatment of psoriasis. It is a topical cream formulation being studied in clinical development. MK-0873 2% is also known as MK-0873 2% Cream.
MK-0873 2% is being studied for the treatment of plaque psoriasis, a chronic inflammatory skin condition. It is a topical cream applied to the skin. The drug is investigational and has not been approved for any indication.
MK-0873 2% targets phosphodiesterase 4 (PDE4), specifically the PDE4A, PDE4B, PDE4C, and PDE4D subtypes. It acts as a PDE4 inhibitor. By inhibiting PDE4, the drug is designed to modulate inflammatory signaling pathways involved in psoriasis.
MK-0873 2% is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program evaluating the topical cream for plaque psoriasis.
MK-0873 2% is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any regulatory authority. The Phase 1 trial has been completed.
MK-0873 2% was evaluated in one completed Phase 1 trial, NCT01235728, titled A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis. The trial enrolled 24 participants in the United States and was randomized, double-blind, and controlled.